Universal Beteiligungs und Servicegesellschaft mbH Sells 41,705 Shares of Progyny, Inc. $PGNY

Universal Beteiligungs und Servicegesellschaft mbH cut its position in Progyny, Inc. (NASDAQ:PGNY) by 35.5% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 75,626 shares of the company’s stock after selling 41,705 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Progyny were worth $1,627,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Amalgamated Bank increased its stake in shares of Progyny by 8.7% during the 3rd quarter. Amalgamated Bank now owns 23,008 shares of the company’s stock worth $495,000 after purchasing an additional 1,833 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in Progyny during the third quarter worth about $487,000. Versant Capital Management Inc increased its position in Progyny by 61.8% during the third quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock worth $50,000 after buying an additional 894 shares during the last quarter. Nordea Investment Management AB increased its position in Progyny by 2.3% during the third quarter. Nordea Investment Management AB now owns 187,601 shares of the company’s stock worth $3,955,000 after buying an additional 4,239 shares during the last quarter. Finally, Bayforest Capital Ltd raised its stake in Progyny by 2,106.3% in the third quarter. Bayforest Capital Ltd now owns 35,058 shares of the company’s stock valued at $754,000 after buying an additional 33,469 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

Insider Buying and Selling at Progyny

In related news, CFO Mark S. Livingston sold 21,303 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $25.50, for a total value of $543,226.50. Following the transaction, the chief financial officer owned 48,358 shares in the company, valued at approximately $1,233,129. This trade represents a 30.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Peter Anevski purchased 79,500 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The stock was bought at an average cost of $24.29 per share, with a total value of $1,931,055.00. Following the purchase, the chief executive officer owned 680,251 shares of the company’s stock, valued at $16,523,296.79. This represents a 13.23% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have sold 22,046 shares of company stock worth $561,691. 9.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PGNY. Barclays initiated coverage on Progyny in a report on Monday, December 8th. They set an “overweight” rating and a $29.00 target price on the stock. JPMorgan Chase & Co. set a $35.00 price objective on shares of Progyny in a research report on Wednesday, January 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a report on Monday, December 29th. Truist Financial raised shares of Progyny from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a report on Thursday, January 8th. Finally, Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.36.

Progyny Stock Down 1.0%

Shares of Progyny stock opened at $23.87 on Friday. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of 37.89, a price-to-earnings-growth ratio of 1.53 and a beta of 0.93. Progyny, Inc. has a twelve month low of $17.98 and a twelve month high of $28.75. The company has a 50-day simple moving average of $25.65 and a two-hundred day simple moving average of $23.33.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, November 6th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.39 by $0.06. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The company had revenue of $313.35 million for the quarter, compared to analysts’ expectations of $299.23 million. During the same period last year, the firm earned $0.11 earnings per share. The business’s revenue for the quarter was up 9.3% on a year-over-year basis. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. On average, sell-side analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.